Paper40319178
Deacetylation of ANXA2 by SIRT2 desensitizes hepatocellular carcinoma cells to donafenib via promoting protective autophagy.
Sun L and 16 others. Cell Death Differ, 2025. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Deacetylation of ANXA2 by SIRT2 desensitizes hepatocellular carcinoma cells to donafenib via promoting protective autophagy. Papers, record 40319178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40319178
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Deacetylation of ANXA2 by SIRT2 desensitizes hepatocellular carcinoma cells to donafenib via promoting protective autophagy.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Sirtuin 2 | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Autophagy | Major topic |
| Liver Neoplasms | Major topic |
| Annexin A2 | Major topic |
| Pyridines | Major topic |
| Humans | |
| Acetylation | |
| Cell Line, Tumor |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82273114 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 82073300 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 32300626 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| 82273112 | National Natural Science Foundation of China (National Science Foundation of China) | PubMed | ||
| CSTB2022NSCQ-LZX0018 | Natural Science Foundation of Chongqing (Natural Science Foundation of Chongqing Municipality) | PubMed | ||
| CSTB2023NSCQ-MSX0651 | Natural Science Foundation of Chongqing (Natural Science Foundation of Chongqing Municipality) | PubMed | ||
| 2022XQN05 | Third Military Medical University (TMMU) | PubMed |
Source PubMed
References51
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28166203 | LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. | Oncogene | 2017 | https://conductscience.org/library/papers/28166203 | PubMed |
| 2 | 18332217 | The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. | J Cell Biol | 2008 | https://conductscience.org/library/papers/18332217 | PubMed |
| 3 | 25484070 | Posttranslational modification of autophagy-related proteins in macroautophagy. | Autophagy | 2015 | https://conductscience.org/library/papers/25484070 | PubMed |
| 4 | 28465257 | 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. | Cancer Lett | 2017 | https://conductscience.org/library/papers/28465257 | PubMed |
| 5 | 36369487 | Evolving therapeutic landscape of advanced hepatocellular carcinoma. | Nat Rev Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/36369487 | PubMed |
| 6 | 39097092 | ADAM8 deficiency in macrophages promotes cardiac repair after myocardial infarction via ANXA2-mTOR-autophagy pathway. | J Adv Res | 2025 | https://conductscience.org/library/papers/39097092 | PubMed |
| 7 | 2960386 | Annexins--new family of Ca2+-regulated-phospholipid binding protein. | Biosci Rep | 1987 | https://conductscience.org/library/papers/2960386 | PubMed |
| 8 | 35042977 | Modulation of cellular processes by histone and non-histone protein acetylation. | Nat Rev Mol Cell Biol | 2022 | https://conductscience.org/library/papers/35042977 | PubMed |
| 9 | 35250553 | Sorafenib-Induced Autophagy Promotes Glycolysis by Upregulating the p62/HDAC6/HSP90 Axis in Hepatocellular Carcinoma Cells. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/35250553 | PubMed |
| 10 | 29433850 | Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. | Lancet | 2018 | https://conductscience.org/library/papers/29433850 | PubMed |
| 11 | 30081903 | ANXA2 promotes esophageal cancer progression by activating MYC-HIF1A-VEGF axis. | J Exp Clin Cancer Res | 2018 | https://conductscience.org/library/papers/30081903 | PubMed |
| 12 | 36931971 | Recent advances in targeting autophagy in cancer. | Trends Pharmacol Sci | 2023 | https://conductscience.org/library/papers/36931971 | PubMed |
| 13 | 33872660 | Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. | Life Sci | 2021 | https://conductscience.org/library/papers/33872660 | PubMed |
| 14 | 33602787 | HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness. | Cancer Res | 2021 | https://conductscience.org/library/papers/33602787 | PubMed |
| 15 | 27634758 | NRBP2 Overexpression Increases the Chemosensitivity of Hepatocellular Carcinoma Cells via Akt Signaling. | Cancer Res | 2016 | https://conductscience.org/library/papers/27634758 | PubMed |
| 16 | 34591285 | Donafenib: First Approval. | Drugs | 2021 | https://conductscience.org/library/papers/34591285 | PubMed |
| 17 | 35474212 | Annexin A2: The diversity of pathological effects in tumorigenesis and immune response. | Int J Cancer | 2022 | https://conductscience.org/library/papers/35474212 | PubMed |
| 18 | 22705595 | Clinical and prognostic role of annexin A2 in multiple myeloma. | Blood | 2012 | https://conductscience.org/library/papers/22705595 | PubMed |
| 19 | 34624198 | Current epidemiology in hepatocellular carcinoma. | Expert Rev Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34624198 | PubMed |
| 20 | 38290972 | ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells. | Autophagy | 2024 | https://conductscience.org/library/papers/38290972 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42765004 | Nanomaterial-driven spatiotemporal autophagy modulation: The dual-edged sword in precision cancer therapy. | Acta Pharm Sin B | 2026 | https://conductscience.org/library/papers/42765004 | PubMed |
| 42512290 | Epigenetic Alterations in Hepatocellular Carcinoma: Mechanisms and Biomarkers for Precision Therapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42512290 | PubMed |
| 42404106 | Emerging Role of Sirtuins-Mediated Ferroptosis in Hepatocellular Carcinoma Progression: Mechanisms and Therapeutic Perspectives. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42404106 | PubMed |
| 42310746 | SerpinB7 promotes c-Myc-mediated glycolysis by interacting with ANXA2 to facilitate the progression of non-small cell lung cancer. | Mol Cancer | 2026 | https://conductscience.org/library/papers/42310746 | PubMed |
| 42213854 | CEMs-SELEX: DNAzyme-powered de novo biomarker discovery and noninvasive cancer diagnosis. | Sci Adv | 2026 | https://conductscience.org/library/papers/42213854 | PubMed |
| 42089471 | The role of Annexin A2 in Alzheimer's disease: From cellular functions to therapeutic potential. | FEBS J | 2026 | https://conductscience.org/library/papers/42089471 | PubMed |
| 41425553 | Sirtuins and tumor immunity: mechanistic insights, immunotherapy prospects, and therapeutic horizons. | Front Immunol | 2025 | https://conductscience.org/library/papers/41425553 | PubMed |
| 41185558 | VSIG2 hinders gastric cancer progression by suppressing ANXA2-mediated NF-κB pathway activation. | Acta Biochim Biophys Sin (Shanghai) | 2025 | https://conductscience.org/library/papers/41185558 | PubMed |
| 41108510 | Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential. | Med Oncol | 2025 | https://conductscience.org/library/papers/41108510 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ANXA2 | 302 | PubTator's text mining | https://conductscience.org/library/genes/302 | NCBI Gene |
| EP300 | 2033 | PubTator's text mining | https://conductscience.org/library/genes/2033 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| SIRT2 | 22933 | PubTator's text mining | https://conductscience.org/library/genes/22933 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40319178
GET https://conductscience.org/api/papers/v1/40319178/references?page=2